Valeris

What They Do

Valeris is a fully integrated life sciences commercialization platform formed in May 2025 through the merger of two PE-backed companies — PharmaCord (Permira-backed, Jeffersonville, IN; hub services specialist founded 2017 by Nitin Sahney) and Mercalis (Odyssey Investment Partners-backed, Morrisville, NC; formerly TrialCard, founded 2000; end-to-end platform built through 7+ acquisitions) (Valeris launch PR).

Heritage: TrialCard → Mercalis → Valeris

The Mercalis half of Valeris traces back to TrialCard, founded in 2000 in Cary, North Carolina, as one of the original pioneers of pharmaceutical copay card programs in the United States. TrialCard grew to become the self-described “largest provider of patient access programs in the industry,” processing over $1B in reimbursement benefits per year by 2015 and holding nine U.S. patents related to patient access program processing (Odyssey Investment Partners).

The company passed through three successive PE sponsors, each driving a capability expansion:

• Excellere Partners (2015-2017): Acquired TrialCard under CEO Mark Bouck; partnership named Deal of the Year by ACG Raleigh-Durham. Expanded beyond copay cards into adherence, reimbursement support, and analytics.
• Odyssey Investment Partners (2017-2025): Executed an aggressive M&A strategy with 8 acquisitions in 7 years — including TC Script (non-commercial pharmacy, 2018), RxSolutions (patient access, 2019), Mango Health (mobile adherence, 2019), Policy Reporter (payer intelligence, 2019), Archer Healthcare (HCP engagement/FRM, 2021), and Triangle Insights Group (market access consulting, 2022). TrialCard posted 42% organic revenue growth in 2019 and 44% in 2018, ranking among the fastest-growing private companies in the Research Triangle (Mercalis).
• Rebrand to Mercalis (September 2023): TrialCard formally rebranded as Mercalis — “simple shorthand for ‘commercializing life sciences’” — marking the shift from copay card company to full life sciences commercialization platform. At the time: 1,800+ employees, 500+ life sciences clients (PR Newswire).
• Permira merger → Valeris (May 2025): Mercalis merged with PharmaCord (acquired by Permira September 2024) to form Valeris. Robert Truckenmiller (PharmaCord CEO) became CEO; Scott Dulitz (Mercalis CEO) became President.

The combined entity delivers a three-pillar model:

Insights & Data: Pre-approval market access strategy via Triangle Insights Group (acquired by Mercalis in 2022), real-time payer intelligence via Policy Reporter (tracking formulary changes, coverage policies, PA requirements, and OOP costs across UHC, CVS Health, and hundreds of other payers), and analytics/advisory.

Patient Support Services: Hub services (benefit investigation, PA, case management), co-pay/PAP programs, bridge programs, free trial/vouchers, DTP (direct-to-patient) pharmacy, field reimbursement, nursing support, and adherence programs. Operated through a multi-site non-commercial pharmacy network (Louisville, Scottsdale, and Digital Intake Pharmacy in NC) capable of 600 dispenses/hour at 99.999% accuracy with full serialized track-and-trace (Permira/FiercePharma whitepaper).

Healthcare Provider Engagement: Scalable HCP outreach, lead generation, education, eServices (ePA, eBV), and EngageHCP tools.

Competitive Positioning

Valeris is positioned as a Tier 1 independent platform — the PE thesis is explicitly to become “the largest independent U.S. market access and patient services partner” by 2030. The core differentiation claim: the only independent with pre-approval strategy + real-time payer intelligence + hub services + affordability + DTP pharmacy under one roof.

vs. Eversana (~$1B+ revenue, 6,000 employees): Eversana includes contract field sales and is larger overall. Valeris positions as more specialized on access/hub/data, with stronger upstream market access advisory capabilities (Triangle Insights, Policy Reporter) that Eversana lacks (Permira/FiercePharma whitepaper).

vs. ConnectiveRx ($357-$681M revenue est.): ConnectiveRx focuses primarily on affordability/co-pay and hub. Valeris adds upstream market access strategy and real-time payer intelligence — capabilities ConnectiveRx lacks. TrialCard heritage gives Valeris particular depth in copay accumulator/maximizer mitigation (patented algorithms, TrialCard Pay for Best Price compliance, TC Synapse fraud detection) — an area where ConnectiveRx has less documented capability. However, ConnectiveRx’s eRx/pharmacy-workflow integration gives it stronger point-of-prescribing activation rates that Valeris’s TrialCard-era architecture does not match.

vs. Cencora/Lash Group: Lash’s parent (Cencora, ~$270B revenue) provides resource advantage but also complexity and distributor conflict-of-interest. Valeris positions as the manufacturer-aligned independent with more agile technology.

vs. CareMetx: CareMetx is a specialty-hub specialist with deep EHR/EMR integration. Valeris (via TrialCard heritage) brings broader copay and affordability capabilities alongside hub services. In specialty/rare disease categories where EHR-native workflows matter most, CareMetx has domain-specific depth. Valeris counters with greater breadth and the Policy Reporter payer intelligence layer.

vs. Neovance: Most similar model (PE-backed hub + owned non-commercial SP + FRM). Valeris is significantly larger and adds the upstream advisory/intelligence layer.

Recent Developments (2017-2026)

TrialCard / Mercalis Era (2017-2025)

• November 2017: Odyssey Investment Partners acquires TrialCard from Excellere Partners.
• 2018-2019: TrialCard executes 4 acquisitions (TC Script, RxSolutions, Mango Health, Policy Reporter) and posts 44% (2018) and 42% (2019) organic revenue growth.
• 2019: Policy Reporter acquisition gives TrialCard a proprietary payer intelligence moat — the asset that would become one of Valeris’s key differentiators.
• 2021: Archer Healthcare acquisition adds HCP engagement and field reimbursement capabilities; TrialCard wins prime HHS contract for “Ready, Set, PrEP” program (free PrEP medications to uninsured individuals, with AssistRx and Cardinal Health as subcontractors).
• 2022: Triangle Insights Group acquisition adds upstream market access strategy consulting; CEO transition from Mark Bouck to Scott Dulitz (July 2022); PatientLink digital PSP platform launched (April 2022).
• September 2023: TrialCard rebrands as Mercalis — marking its transformation from copay card company to full commercialization platform.
• September 2024: Policy Reporter / Turquoise Health strategic data partnership; Permira completes acquisition of PharmaCord.

Valeris Era (2025-Present)

• June 2024: Permira announces substantial investment in PharmaCord (terms undisclosed). Closed September 2024 (Permira).
• March 2025: PharmaCord and Mercalis announce merger; Permira as majority owner (Permira merger announcement).
• May 27, 2025: Merger completes; combined company rebrands as Valeris (PR Newswire).
• July-September 2025: Major C-suite builds — Jodi Dickinson (CPO), Peter Formisano (COO), Manish Goel (CTO, ex-IQVIA CTO) join.
• January 2026: Reports strong FY2025 results — exceeded financial targets and new business goals; Patient Support Services added 20+ new partners; Policy Reporter achieved >20% YoY revenue growth (Valeris FY2025 PR).
• February 2026: First-in-market capability to detect and disrupt medical benefit maximizer activity via Policy Reporter — identified 200+ brands targeted under medical benefit maximizer health plans (PR Newswire).
• April 7, 2026: Scott Filosi appointed Chief Commercial Officer — nearly 3 decades commercial leadership at Merck KGaA, UCB, Verona Pharma, Boehringer Ingelheim, J&J (Valeris).
• No post-formation acquisitions announced as of April 2026 despite M&A being an explicit strategy.

Client Types & Therapeutic Focus

Serves 500+ life sciences customers and 275+ drug brands actively. Mercalis alone had relationships with 19 of the top 20 global pharma companies pre-merger. The company has supported 44M+ patients and delivered $34B+ in patient savings over its combined history (Permira portfolio, Valeris). TrialCard-era metrics provide additional scale context: 35M+ cumulative patients served and $18B+ in cumulative branded drug savings by 2021, with $2.6B in annual patient cost-sharing savings in 2019 alone (Mercalis). TrialCard also ranked #2 on the Triangle Business Journal Fast 50 in 2021 and #5 in 2020.

Therapeutic focus: oncology, rare diseases/orphan drugs, CNS, specialty lite / GLP-1s (explicitly highlighted as a strategic growth area with dedicated DTP infrastructure), cell and gene therapies, and immunology. Valeris launched innovative oncology patient services programs in 2024 and expanded into CNS (Mercalis 2024 highlights).

Technology

Platform	Description
Policy Reporter	Proprietary SaaS payer intelligence platform; real-time formulary, coverage, PA tracking across hundreds of payers; >20% YoY revenue growth; first-in-market medical benefit maximizer detection
CLS (Connect for Life Sciences)	Salesforce Health Cloud-based patient hub platform (built at Mercalis)
PharmaCord Lynk	PharmaCord’s legacy proprietary technology suite, now integrated
AI-Powered Contact Center	Built on Cisco Webex with conversational AI; intelligent call routing
IDP (Intelligent Document Processing)	40% enrollment processing time savings (20-30 min to 5 min)
eServices Suite	ePA (benefit-agnostic), automated PA follow-up, eBV, eServices Curator
Next-Gen Co-Pay Platform	Identifies patient insurance data to reduce copay spend 10-20%; auto-initiates ePA during enrollment
QuickPath	TrialCard-era patient management platform with real-time API integration to EHRs and e-prescribing systems; supports eBV and ePA (Drug Channels)
PatientLink	Enterprise SaaS PSP platform (launched 2022) with omnichannel engagement, online eligibility, copay estimator; designed to shift 80%+ of copay-related inbound calls to digital self-serve (PR Newswire)
TC Catalyst	TrialCard-era reporting/analytics platform integrating hub, copay, pharmacy dispense, payer/PBM claims, and patient-reported outcomes data
TC Synapse	Compliance and risk mitigation suite protecting against pharmacy fraud, copay accumulators/maximizers, government exclusion violations, and discount card disruption
TrialCard Pay	Digital reimbursement solution (ACH/Zelle) enabling Best Price compliance while mitigating copay accumulator impacts (Mercalis)
RxStudy Card	Clinical trial supply management solution used by more than half of the top biopharma companies and CROs in the U.S.

ISO/IEC 27001 certified (held since 2018). Voice AI for patient engagement in development for 2026 roadmap. Tech Advisory Council and Patient Excellence Advisory Council established by Permira for governance (Permira/FiercePharma whitepaper).

Financial Context

Metric	Detail
Investment terms	Undisclosed (both Permira/PharmaCord and Mercalis merger)
Revenue estimate	$400M-$800M post-merger (directional, based on scale comparables); Mercalis standalone est. $150M-$250M pre-merger (third-party estimates range $87M-$200M; adjusted for 42-44% organic growth and 8 acquisitions)
Employees	2,500+ specialists (Permira portfolio); est. 2,500-3,500 combined
Ownership	Permira (majority), Odyssey Investment Partners (minority)
Permira AUM	~EUR 80B across PE and credit
FY2025	Exceeded financial targets; every business line posted strong growth
2030 ambition	”Nearly double current size” to become largest independent U.S. market access/patient services partner

PharmaCord had built a purpose-built $52M+ operations center in Jeffersonville, IN, creating 850+ jobs by 2023 (Clark County). Notable: PharmaCord founder Nitin Sahney transitioned out of Valeris leadership post-merger (now at Sahney Ventures as of January 2025).

M&A advisors on the merger: Harris Williams (financial, Odyssey/Mercalis), Jefferies and Leerink Partners (financial, PharmaCord), Latham & Watkins (legal, Mercalis), Skadden Arps (legal, PharmaCord) (BioSpace).

Analyst Observations

1. The medical benefit maximizer detection (Feb 2026) is the most interesting near-term product move. Policy Reporter’s ability to identify 200+ brands targeted by medical benefit maximizer health plans addresses a growing pain point for pharma manufacturers losing copay investment to payer arbitrage. This is a genuinely novel capability that competitors haven’t matched yet.

2. The “no acquisitions yet” gap is notable. Permira explicitly stated M&A as a strategic lever, and the merger’s advisory infrastructure (Jefferies, Leerink, Skadden) signals serious deal-making capability. Yet 11 months post-formation, no add-on acquisitions have been announced. This could reflect integration discipline or difficulty finding targets at acceptable valuations. The 2026-2027 period should see Valeris become acquisitive if the platform thesis holds.

3. The founder departure is a double-edged signal. Nitin Sahney (PharmaCord founder) leaving the combined entity suggests either a planned founder exit or strategic disagreement with Permira’s integration direction. This is common in PE mergers but worth noting — PharmaCord’s cultural identity (founder-led, tech-first, high NPS) may dilute as the combined entity scales. The rapid C-suite hiring (CTO, COO, CPO, CCO all new in 2025-2026) indicates Permira is building for scale over continuity.

4. The TrialCard copay heritage is a genuine but buried asset. TrialCard was a top-3 copay vendor with 9 patents, proprietary accumulator/maximizer detection algorithms (their 2017 analysis showed 5% of patients in accumulator programs consumed 40% of manufacturer benefit at ~$18K/patient), and specialized tools like TrialCard Pay and TC Synapse. This copay expertise now sits three rebrands deep inside a platform company. The risk is that buyers seeking a focused copay specialist may not recognize or access this capability within Valeris. The opportunity is that the February 2026 medical benefit maximizer detection capability (via Policy Reporter) shows the TrialCard copay DNA is still actively driving product innovation — the payer intelligence asset acquired in the TrialCard era is now producing Valeris’s most differentiated new capability.

5. Three PE sponsors in a decade is unusual and worth watching. Excellere (2015) → Odyssey (2017) → Permira (2025) means TrialCard/Mercalis has been through three ownership transitions. Each brought capital and strategic direction, but also leadership churn (Mark Bouck out in 2022, Dulitz moved from CEO to President in 2025) and potential service continuity risk for long-standing clients. The 42-44% organic growth rates under Odyssey (2018-2019) demonstrate the underlying business quality, but buyers should probe whether the integration complexity of the Valeris merger has disrupted the copay team’s velocity.

6. The HHS “Ready, Set, PrEP” contract (2021) is an underappreciated credential. Winning a prime government contract for national PrEP access — with AssistRx and Cardinal Health as subcontractors — demonstrates operational maturity and compliance capability that few competitors can match. This credential carries forward into Valeris.

Related concepts: Copay Accumulator & Maximizer, Gross-to-Net, PE Consolidation in Pharma Services

Sources

• Valeris.com
• Valeris Launch PR
• Permira portfolio
• Permira/FiercePharma whitepaper
• Valeris FY2025 PR
• Medical benefit maximizer PR
• Permira PharmaCord investment
• BioSpace merger announcement
• Mercalis 2024 highlights
• Clark County - PharmaCord operations center
• Wave 3 research: wiki/raw/research/wave3-batch-a-hub-vendors.md
• TrialCard heritage research: wiki/raw/research/trialcard_vendor_profile.md
• Odyssey Investment Partners — TrialCard Acquisition (2017)
• TrialCard Copay Accumulator Analysis — Drug Channels (2018)
• TrialCard Hub Services — Drug Channels (2019)
• Mercalis Rebrand Announcement (2023)
• Excellere Partners — TrialCard Deal of the Year (2015)
• PatientLink Launch (2022)
• Mercalis — HHS Ready, Set, PrEP Contract (2021)
• PM360 — Scott Dulitz Elite 2024
• TrialCard Pay — Best Price compliance